NASDAQ:LPCN

Lipocine (LPCN) News Today

$3.32

+0.03 (+0.91%)

(As of 12:28 PM ET)

Compare

Today's Range: $3.25
▼
$3.33
50-Day Range: $3.22
▼
$5.10
52-Week Range: $3.22
▼
$10.33

Volume: 2,935 shs
Average Volume: 70,673 shs
Market Capitalization: $17.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $68.00

Source

Source	Headline
	Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com americanbankingnews.com - September 20 at 3:22 AM
	Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference finance.yahoo.com - September 19 at 5:11 PM
	StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) americanbankingnews.com - September 12 at 3:18 AM
	Looking for a Value Investment? Check out These 3 Pharma Stocks stocknews.com - August 17 at 3:01 PM
	LPCN: Trial Results Improve Outlook finance.yahoo.com - August 16 at 10:13 AM
	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 finance.yahoo.com - August 10 at 8:29 AM
	LPCN: 1148 Shows Muscle Loss Reversal finance.yahoo.com - July 31 at 6:25 PM
	Why Lipocine Stock Is Moving Higher Today? benzinga.com - July 27 at 1:35 PM
	Why Is Lipocine (LPCN) Stock Up 32% Today? investorplace.com - July 27 at 9:14 AM
	Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference finance.yahoo.com - June 14 at 12:35 PM
	Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 finance.yahoo.com - June 7 at 8:57 AM
	Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression msn.com - May 16 at 2:41 PM
	Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression finance.yahoo.com - May 16 at 9:40 AM
	Recap: Lipocine Q1 Earnings msn.com - May 12 at 9:17 AM
	Lipocine: Q1 Earnings Snapshot apnews.com - May 11 at 8:00 AM
	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 finance.yahoo.com - May 11 at 8:00 AM
	First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 finance.yahoo.com - April 3 at 10:47 AM
	LPCN: 2022 Operational & Financial Update finance.yahoo.com - March 16 at 1:39 PM
	Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock finance.yahoo.com - March 10 at 9:22 AM
	Lipocine Announces Financial Results for the Year Ended December 31, 2022 finance.yahoo.com - March 10 at 9:22 AM
	Is Lipocine Inc.'s (NASDAQ:LPCN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? finance.yahoo.com - January 16 at 1:03 PM
	Lipocine to Present at Biotech Showcase finance.yahoo.com - January 5 at 9:32 AM
	Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis finance.yahoo.com - December 19 at 10:18 AM
	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022 finance.yahoo.com - November 9 at 8:48 AM
	Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline finance.yahoo.com - November 3 at 9:28 AM
	Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference - Yahoo Finance finance.yahoo.com - October 11 at 5:52 PM
	Lipocine to Present at H.C. Wainwright 6th Annual NASH Investor Conference finance.yahoo.com - October 11 at 12:52 PM
	Lipocine to Participate in the Cantor Neurology & Psychiatric Conference - PR Newswire prnewswire.com - September 27 at 8:11 PM
	Lipocine to Participate in the Cantor Neurology & Psychiatric Conference finance.yahoo.com - September 27 at 3:11 PM
	Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% - Seeking Alpha seekingalpha.com - September 27 at 10:10 AM
	Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets finance.yahoo.com - September 26 at 6:43 PM
	Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders - PR Newswire prnewswire.com - September 26 at 8:43 AM
	Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders finance.yahoo.com - September 26 at 8:43 AM
	Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - Yahoo Finance finance.yahoo.com - September 23 at 9:21 AM
	Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference - PR Newswire prnewswire.com - September 22 at 4:32 PM
	Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference finance.yahoo.com - September 22 at 4:32 PM
	Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - PR Newswire prnewswire.com - September 19 at 3:48 AM
	Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) - Yahoo Finance finance.yahoo.com - September 16 at 3:09 PM
	Lipocine Announces Favorable Regulatory Pathway On LPCN 1154 For Post-Partum Depression - Nasdaq nasdaq.com - September 15 at 9:05 AM
	Lipocine (NASDAQ:LPCN) – Lipocine Announces Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depressi - Benzinga benzinga.com - September 15 at 9:05 AM
	Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) finance.yahoo.com - September 15 at 9:05 AM
	LPCN: TLANDO Launched finance.yahoo.com - August 10 at 3:47 PM
	Lipocine Inc. (NASDAQ:LPCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? finance.yahoo.com - August 9 at 7:44 AM
	Lipocine: Q2 Earnings Snapshot apnews.com - August 8 at 9:43 PM
	Recap: Lipocine Q2 Earnings - Benzinga benzinga.com - August 8 at 4:43 PM
	Form 10-Q Lipocine Inc. For: Jun 30 - StreetInsider.com streetinsider.com - August 8 at 4:43 PM
	Lipocine GAAP EPS of -$0.04 in-line, revenue of $0.5M beats by $0.24M (NASDAQ:LPCN) - Seeking Alpha seekingalpha.com - August 8 at 4:43 PM
	Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com streetinsider.com - August 8 at 4:43 PM
	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 - PR Newswire prnewswire.com - August 8 at 4:42 PM
	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 finance.yahoo.com - August 8 at 4:42 PM

Get Lipocine News Delivered to You Automatically

LPCN Media Mentions By Week

LPCN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LPCN
News Sentiment
▼
0.17

0.54
▲
Average
Medical
News Sentiment

LPCN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LPCN Articles
This Week
▼
2

0
▲
LPCN Articles
Average Week

Get Lipocine News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:LPCN) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Lipocine (LPCN) News Today

LPCN Media Mentions By Week

LPCN Media Sentiment

LPCN News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info